David Drutz

Background

About David Drutz

Dr. Drutz is President of Pacific Biopharma Associates, founded in association with his role as general partner with Pacific Rim Ventures (Tokyo; Yokohama - Board of director activities include Altimmune, Inc (NASDAQ:ALT), 2010-2024 – Chairman, 2011-2017; Tranzyme Pharma (NASDAQ:TZYM)- Chairman, MethylGene Inc (TSX:MYG), Gentris Corporation (2007-2014); and DARA BioSciences (NASDAQ:DARA)- Executive Chairman, CEO, and CMO (2012-2017). In addition, he has served on several scientific advisory boards in the area of metabolic syndrome He is a former member of the Science and Industry Advisory Committee (SIAC) of Genome Canada, advisory to the board regarding genomics investments throughout Canada. Additional management experience includes VP Biological Sciences/VP Clinical Research at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical Corporation, and CEO of Inspire Pharmaceuticals and Sennes Drug Innovations. He received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer in the U.S. Navy with the rank of Lieutenant Commander. He is former Professor and Chief of Infectious Diseases at the University of Texas Health Science Center in San Antonio, where he also served on NIH and VA scientific study sections. He is certified by the American Board of Internal Medicine; a fellow of the American College of Physicians and the Infectious Diseases Society of America; a member of the American Society of Clinical Oncology, the American Society for Clinical Investigation and Alpha Omega Alpha Honor Medical Society; and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation. In 2019 he was recipient of both the Albert Nelson Marquis Who's Who Lifetime Achievement Award and the Who's Who Top Executive Award.